written by Michael O’Leary
Last week an FDA advisory panel recommended degludec, a once-daily injectable insulin, be approved by the FDA, but will require Novo Nordisk to conduct additional trials to assess the heart risk that may be posed by the drug.
As reported by Fierce BiotechReuters and others the outside panel of non-FDA medical experts recommended approval by an 8-4 vote, but unanimously voted to require additional studies to assess the heart risk.
(published site)